ストックスクリーナーアプリを入手
10.31
1.38%
0.14
アフターアワーズ：
10.40
0.09
+0.87%
前日終値:
$10.17
開ける：
$10.17
24時間の取引高:
6.28M
Relative Volume:
0.68
時価総額：
$12.02B
収益：
$14.33B
当期純損益:
$-3.79B
株価収益率:
-3.2524
EPS:
-3.17
ネットキャッシュフロー:
$1.84B
1週間 パフォーマンス:
+4.56%
1か月 パフォーマンス:
+4.14%
6か月 パフォーマンス:
+36.38%
1年 パフォーマンス:
-12.33%
1日の値動き範囲:
$10.13
$10.32
1週間の範囲:
$9.73
$10.32
52週間の値動き範囲:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
VTRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
10.31 | 11.86B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
145.06 | 63.85B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.08 | 44.34B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.41 | 42.21B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.42 | 22.15B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
432.69 | 19.60B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-06-06 | 開始されました | Goldman | Neutral |
| 2024-07-19 | 再開されました | Jefferies | Buy |
| 2023-10-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2023-04-24 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-02-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-10 | アップグレード | UBS | Sell → Neutral |
| 2022-11-08 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 再開されました | Jefferies | Hold |
| 2022-06-14 | 開始されました | UBS | Sell |
| 2022-05-10 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 開始されました | Citigroup | Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2021-03-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-02-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 開始されました | Argus | Hold |
| 2020-12-14 | 開始されました | Bernstein | Mkt Perform |
すべてを表示
Viatris Inc (VTRS) 最新ニュース
What’s the recovery path for long term holders of Viatris Inc.July 2025 Momentum & Daily Chart Pattern Signals - newser.com
Will Viatris Inc. stock benefit from upcoming earnings reportsShort Setup & Capital Efficiency Focused Strategies - newser.com
Viatris buys Aculys Pharma to expand neurology portfolio in Japan - Medical Dialogues
Relative strength of Viatris Inc. in sector analysisInsider Selling & High Yield Stock Recommendations - newser.com
How cyclical is Viatris Inc. (VIA) stock compared to rivals2025 Big Picture & Technical Entry and Exit Tips - nchmf.gov.vn
Is Viatris Inc. stock vulnerable to regulatory risksTreasury Yields & Free Weekly Watchlist of Top Performers - nchmf.gov.vn
Why analysts remain bullish on Viatris Inc. stockWeekly Trade Review & Precise Trade Entry Recommendations - nchmf.gov.vn
Is Viatris Inc. stock a safe investment in uncertain marketsTreasury Yields & Daily Momentum Trading Reports - nchmf.gov.vn
Will Viatris Inc. stock see insider buying2025 Key Lessons & Real-Time Volume Spike Alerts - nchmf.gov.vn
Market Outlook: Is Viatris Inc. (VIA) stock resilient in recession scenariosJuly 2025 Review & Low Risk High Reward Trade Ideas - nchmf.gov.vn
Hedge Fund Bets: Will Viatris Inc. stock see insider buyingWeekly Stock Summary & Low Risk High Reward Trade Ideas - nchmf.gov.vn
Teva Vs. Viatris: Who Will Dominate In President Trump's America? (NASDAQ:VTRS) - Seeking Alpha
How Recent Developments Are Reshaping the Viatris Investment Story - Yahoo Finance
Viatris (VTRS): Taking a Fresh Look at Valuation After Recent Share Price Rebound - Yahoo Finance
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan - Yahoo Finance
How Viatris Prevents and Manages NCDs - CSRwire
Viatris completes Aculys Pharma acquisition - Seeking Alpha
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region - PR Newswire
Truist Securities initiates Viatris stock with Buy rating, sets $15 target By Investing.com - Investing.com South Africa
Truist Securities initiates Viatris stock with Buy rating, sets $15 target - Investing.com Nigeria
Night Vision Disturbances Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Ocuphire Pharma, Viatris - Barchart.com
Is Viatris Inc. stock a good choice for value investorsJuly 2025 Sentiment & Community Verified Trade Alerts - newser.com
Can trapped investors hope for a rebound in Viatris Inc.Market Movement Recap & Step-by-Step Trade Execution Guides - newser.com
Heron settles patent dispute with Viatris over antiemetic agents - MSN
Pattern recognition hints at Viatris Inc. upsideJuly 2025 Market Mood & Proven Capital Preservation Methods - newser.com
Viatris to Participate in Upcoming Investor Conferences - Nasdaq
Viatris Inc. (VTRS) Stock Analysis: Exploring a 17.34% Potential Upside Amidst Healthcare Sector Dynamics - DirectorsTalk Interviews
Developing predictive dashboards with Viatris Inc. data2025 Market Overview & Long-Term Growth Portfolio Plans - newser.com
Viatris Inc. Stock Falls Friday, Still Outperforms Market - 富途牛牛
Does Viatris Offer Opportunity After Recent European Approval Boost? - Yahoo Finance
Kotak Alts-backed Matrix Pharma buys bulk-drugs maker - VCCircle
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga
Viatris’ Work To Advance Access and Public Health - CSRwire
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row - PR Newswire
Viatris shares break six-session winning streak - MSN
Viatris Inc. (VTRS) Investor Outlook: Navigating a 12.15% Potential Upside Amidst Healthcare Challenges - DirectorsTalk Interviews
What analysts say about Viatris Inc stockRSI Overbought/Oversold & Small Entry Cost Trading - earlytimes.in
Morocco fines Viatris 7.58 million dirhams over Mylan-Pfizer merger - MSN
Allergy Treatment Global Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, ALK - PharmiWeb.com
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025 - BioSpace
The Importance of a Global, Resilient Supply Chain to Access - CSRwire
Acute Social Anxiety Disorder Market on Track for Major Expansion by 2034, According to DelveInsight | GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc - Barchart.com
Pharmaceutical Giant Viatris Schedules Q3 2025 Financial Results and Investor Conference Call for November 6 - Stock Titan
Will Viatris Inc. stock continue dividend increasesMarket Performance Summary & Risk Controlled Swing Alerts - newser.com
Viatris Inc. (VTRS) Stock Analysis: Exploring a Potential 20% Upside Amid High Dividend Yield - DirectorsTalk Interviews
Quantitative breakdown of Viatris Inc. recent moveJuly 2025 Gainers & Low Drawdown Momentum Trade Ideas - newser.com
Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineVTRS - 2822news.com
What drives Viatris Inc stock priceBear Market Strategies & Free Unstoppable Trading Performance - earlytimes.in
What drives Viatris Inc VIA stock priceStock Buyback Updates & Build Wealth With Expert Timing Advice - earlytimes.in
What analysts say about Viatris Inc VIA stockCandlestick Trading Patterns & Identify Breakout Stocks - earlytimes.in
Viatris Inc (VTRS) 財務データ
収益
当期純利益
現金流量
EPS
2.08%
0.15%
大文字化:
|
ボリューム (24 時間):